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Background: Brain-derived neurotrophic factor (BDNF) plays an important role in
neuronal plasticity, and its dysregulation has been associated with the pathogenesis of
mood and anxiety disorders. Prolactin (PRL) is a pituitary hormone which is also produced
as a cytokine by immune cells and could be a neurotrophic factor regulating the functional
activity of stress-related mechanisms.
Aim: To investigate the possible relationship between depressive state and BDNF and
PRL genotypes or levels with special reference to severity of depression.
Methods: Participants of 18–70 years with a clinical diagnosis of depressive disorder of at
least moderate severity were included. These patients had not been treated with
antidepressant drugs before admission to hospital during the preceding period of the last
6 months, and 54.5% had never been treated with antidepressant drugs during their entire
life. The DNAwas genotyped for rs1341239 within the prolactin and for rs6265, rs7124442,
and rs11030104 within the BDNF gene. Rs11030104 violated the Hardy-Weinberg
equilibrium distribution and was excluded from further analyses. BDNF and prolactin
concentration was measured in serum by MAGPIX multiplex analyzer (Luminex, USA)
using MILLIPLEX® MAP kit (Merck, Germany). Genetic associations were determined by
sequentially regressing prolactin, BDNF, 17-items Hamilton's Depression (HAMD-17) and
Clinical Global Impression scale, Severity (CGI-S) ratings, and depression (absent/present)
on the available SNPs. Genetic associations were evaluated assuming an additive model.
Results: A total of 186 depressed patients (of which 169 were women) and 94 healthy
controls (67 women) were genotyped. After excluding subjects without genetic information ong February 2020 | Volume 11 | Article 381
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Frontiers in Psychiatry | www.frontiersin.orall three study SNPs, 217 remained of whom 138 suffered from depression.Within depressed
patients we observed an association of rs6265 with HAMD-17: mean difference (MD) 2.33
(95%CI 0.49; 4.16; p = 0.014) and CGI-S: MD 0.38 (95%CI 0.09; 0.66; p = 0.011). No
significant association was observed between the prolactin SNP rs1341239 and prolactin
levels. Similarly the mean differences of BDNF SNPs did not show an association with BDNF:
rs6265 −0.042 ln(pg/ml) (95%CI −0.198; 0.113), and rs7124442 0.006 ln(pg/ml) (95%CI
−0.117; 0.130). No other association reached statistical significance.
Conclusion: We observed a significant association between BDNF gene variant rs6265
and the severity of depression in newly admitted, antidepressant treatment-free,
depressed patients. Actual PRL and BDNF levels were not elevated sufficiently in
depressed patients to reach statistical significance and were not associated with the
studied genotypes.Keywords: major depressive disorder, prolactin, brain derived neurotrophic factor, blood levels, genotypes, rs6265INTRODUCTION
Brain-derived neurotrophic factor (BDNF), discovered in 1982
(1), is a member of the neurotrophin family, also including nerve
growth factor (NGF), neurotrophin-3 (NT-3) , and
neu ro t r oph in - 4 (NT-4 ) ( 2 ) . Nume rou s g en e t i c ,
pharmacological and behavioral studies have linked the
dysregulation of BDNF to major psychiatric and neurological
disorders, including mood and anxiety disorders (3–5).
The human BDNF gene, located on human chromosome
11p14.1, has a complex structure, and its expression is under
sophisticated epigenetic control (3, 6). BDNF genotype and
expression can be expected to modulate BDNF levels and/or its
neuroplastic effects and may, therefore, affect the vulnerability to
develop mood disorders. Most often studied is the single
nucleotide polymorphism (SNP) with a G to A transition on
position 196 in exon 5 of BDNF (rs6265), which results in an
amino acid substitution (valine [Val] to methionine [Met]) at
codon 66 in the precursor BDNF peptide sequence (BDNF
Val66Met). The Met (A) allele induces impaired functioning of
some processes involved in the regulation of extracellular levels
of BDNF (7). However, in spite of these functional consequences,
systematic reviews of the results of association studies suggest
that this BDNF genotype does neither exert a major influence on
the development of depression (7–9), nor on the serum BDNF
levels (10). However, the influence of the Val66Met BDNF
(rs6265) polymorphism may depend on age group, gender, and
ethnicity (7, 11–14). Moreover, according to other meta-analyses
interesting results were obtained concerning an association with
the results of drug treatment (more specifically in Asian gender
and when treated with selective serotonin reuptake inhibitors;
SSRIs) (15, 16) and vulnerability with life stress (17).
The 199 amino-acid hormone prolactin (PRL) is synthesized
and secreted in a pulsatile manner (~ 10 peaks per day in young
adults) by lactotroph cells of the adenohypophysis (18). The gene
that encodes prolactin (PRL) is on chromosome 6p21 (19, 20). In
humans, the PRL locus consists of a single gene that contains five
coding exons, which is controlled by a pituitary-specificg 2promoter, and a non-coding exon, which is controlled by an
alternative promoter. The latter promoter drives expression in
non-pituitary tissues (21). Thus, apart from being a pituitary
hormone, PRL has also a role as a cytokine produced by immune
cells; its receptor belongs to the family of cytokine receptors type
1 (22). A functional polymorphism in the PRL gene, − 1149 G/T
(rs1341239) has been identified of which the G allele was
associated with increased extrapituitary promoter activity and
increased levels of lymphocyte PRL mRNA (23). Hence, PRL
could be one of the cytokines regulating the functional activity of
stress-related mechanisms (5). Ivanova and colleagues have
previously revealed the existence of a significant association
between the polymorphic variant rs1341239 and the
development of hyperprolactinemia in patients with
schizophrenia (18). They suggested that the gene that regulates
extrapituitary PRL production plays a role in regulating stress
response by affecting the immune system. Moreover, prolactin
may have an indirect role by affecting the hypothalamic-
pituitary-adrenal axis. Within the brain, PRL acts as a
neuropeptide to promote physiological responses related to
reproduction, stress adaptation, neurogenes is , and
neuroprotection (24). The action of PRL on the nervous
system contributes to the wide array of changes that occur in
the female brain during pregnancy and result in the attenuation
of the hypothalamic-pituitary-adrenal axis (24). PRL moreover
regulates neurogenesis both in the subventricular zone and in the
hippocampus (24), which may mediate neuroplastic alterations
during chronic stress. Therefore, alterations in the PRL system
due to stress or exposure to substances that reduce neurogenesis
or other conditions could contribute to mood and anxiety
disorders. As far as we know, a possible association between
PRL polymorphisms and depressive disorder had not yet
been studied.
The aim of the present study was to investigate the possible
relationship between being depressed and BDNF and PRL
genotypes, on one hand, serum BDNF and PRL levels on the
other, with special reference to severity of depression.February 2020 | Volume 11 | Article 38
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Patients
This study was carried out in accordance with the Code of Ethics
of the World Medical Association (Declaration of Helsinki 1975,
revised in Fortaleza, Brazil, 2013), and approved by the
Institutional Medical Review Board of the Mental Health
Research Institute (MHRI), Tomsk National Research Medical
Center (protocol 49 from 23.04.12). Participants providing
written informed consent were recruited from newly admitted
patients to our Mental Health Research Institute.
Participants, aged 18–70 years old, were included based on a
clinical diagnosis of depressive episode of a single (ICD: F32) or
recurrent depressive disorder (ICD: F33) (25) with major
depressive episode according to Mini International
Neuropsychiatric Interview (M.I.N.I., 5.0.0) of clinically at least
moderate severity (26). Exclusion criteria were non-Caucasian
ethnicity; schizophrenia, decompensated personality disorders,
pregnancy, or any relevant gynecological or endocrine (thyroid)
disorder; relevant pharmacological withdrawal symptoms; or
organic brain disorders (e.g., epilepsy, Parkinson's disease),
treatment with antidopaminergic drugs (antipsychotic or
antiemetic drugs), and treatment with antidepressant drugs
during the preceding 6 months before admission. These
exclusion criteria intended to avoid artificial intermingling of
the genetic composition of the depressed patient group
(ethnicity, other diagnosis) and/or to avoid factors which
might influence the expression of PRL and/or BDNF
(organicity, pregnancy, endocrinology, drugs).
Control Group
The control group consisted of healthy volunteers who were
actively recruited from society (mainly by advertisements spread
within Tomsk universities and MHRI) and these individuals
were also serving as controls for other patient populations
investigated in the context of this project suffering from
Parkinson's disease or schizophrenia. They were mentally and
somatically healthy individuals of both genders and aged from 18
to 60 years, who provided written informed consent and were of
White physical appearance. Potential control subjects were
excluded if they presented chronic physical pathology in
exacerbation, pregnancy, or any relevant gynecological or
endocrine (thyroid) disorder; relevant pharmacological
withdrawal symptoms; or organic brain disorders (e.g.,
epilepsy, Parkinson's disease) or mental disorders.
Study Design and Ratings
After admission and obtaining informed consent, patients were
diagnosed and assessed within 2 full days and treatment was
initiated immediately thereafter. Depressed subjects were
assessed with the 17-item Hamilton Depression Rating Scale
(HAMD-17) (27, 28) and the Clinical Global Impression scale,
severity (CGI-S) (29).
Blood Sampling
Venous blood samples were drawn from median antecubital vein
after an 8-h overnight fast and collected into evacuated tubesFrontiers in Psychiatry | www.frontiersin.org 3containing EDTA, for DNA extraction, or into tubes with a clot
activator (CAT) to isolate the serum (BD Vacutainer). Blood
samples with EDTA were stored in several aliquots at −20°C,
until the DNA was isolated. Blood samples with CAT were
centrifuged for 20 min at 2,000 g at 4°C to separate the serum;
the serum was stored at −80°C, until prolactin or BDNF analysis.
Multiplex Analysis
BDNF and prolactin concentration was measured in subject's
serum by MAGPIX multiplex analyzer (Luminex, USA) using
MILLIPLEX® MAP kit (Merck, Germany).
Genotyping
The DNA was genotyped for the studied genes in the Laboratory
of Genetics of the University of Groningen with theMassARRAY®
System (Agena Bioscience™) and in the Laboratory of Molecular
Genetics and Biochemistry of the Mental Health Research
Institute using TaqMan® SNP Genotyping Assays with
“StepOnePlus” (Applied Biosystems). Rs1341239 (minor allele
frequency; MAF: 0.38) was measured within the prolactin gene
(position chr6:22303975), and rs6265 (MAF: 0.15), rs7124442
(MAF: 0.27), and rs11030104 (MAF: 0.23) were measured
wi th in the BDNF gene (pos i t ion chr11 :27658369 ;
chr11:27655494; chr11:27662970, accordingly). Rs11030104
violated the Hardy-Weinberg equilibrium distribution and was
excluded from further analyses. Given that rs11030104 was in high
linkage disequilibrium (LD) with rs6265 (R-squared: 0.60) little
information was lost by omitting rs11030104; the remaining SNPs
were in very low LD to each other (see Supplementary Image 1).
Statistical Analysis
Subjects with any missing genetic variant were removed and the
remaining persons were combined in a single data set
(Supplementary Table 1). Genetic associations were
determined by sequentially regressing prolactin, BDNF,
HAMD-17 (both as interval and as a high/low using the
median 24 as cut-off), CGI-S, and depression (absent/present)
on the available SNPs. Generalized linear model was used with
either a Gaussian distribution (continuous or interval outcome
data), or a binomial distribution (binary outcome data), and their
respective canonical link functions. Genetic associations were
evaluated assuming an additive model, this additivity assumption
was evaluated using likelihood ratios tests providing no reasons
to prefer a non-additive model. To reduce the influence of high
prolactin and BDNF values these variables were analyzed on the
natural logarithmic (ln) scale. Results are presented as mean
difference (MD) or odds ratios (ORs) with 95% confidence
intervals (95%CI).RESULTS
Our total genotyped study population comprised of 186
depressed patients (17 male and 169 female) and 94 healthy
persons (27 male and 67 female). Details are provided in Table 1.
After excluding subjects without genetic information on all threeFebruary 2020 | Volume 11 | Article 38
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41 subjects were male, and the mean age was 43.29 years
(standard deviation: 13.58).
The association between age and prolactin was modified by
gender, but not by depression status (Figure 1). With non-
significant age association for male depressed: 0.01 ln(pg/ml)
(95%CI −0.018; 0.047) and healthy men: 0.03 ln(pg/ml) (95%CI
−0.003; 0.067), and significant associations between age and
prolactin in depressed women: −0.02 ln(pg/ml) (95%CI −0.035;
−0.005) as well as healthy women: −0.018 ln(pg/ml) (95%CI
−0.035; −0.005). The prolactin SNP rs1341239 was not associated
with prolactin levels −0.017 ln(pg/ml) (95%CI −0.182; 0.148).
Similarly, the mean differences of BDNF SNPs did not show
an association with BDNF: rs6265 −0.042 ln(pg/ml) (95%CI
−0.198; 0.113), and rs7124442 0.006 ln(pg/ml) (95%CI −0.117;Frontiers in Psychiatry | www.frontiersin.org 40.130). Within depressed patients we observed an association of
rs6265 with HAMD-17 (see Figure 2): mean difference (MD)
2.33 (95%CI 0.49; 4.16; p = 0.014). Categorizing HAMD-17 into
high and low groups did not result in a similar significant effect
for rs6265 (likely due to the limited number of depressed subjects
with two minor alleles) (Figure 2), and neither did the odds ratio
(OR) for depressed versus healthy: 0.62 (95%CI 0.35; 1.11; p =
0.110). The association with CGI-S mirrored those of HAMD-17
with significant findings for rs6265: MD 0.38 (95%CI 0.09; 0.66;
p = 0.011), and without significant associations for rs1341239
MD −0.05 (95%CI −0.24; 0.13) and rs7124442 MD −0.08 (95%CI
−0.26; 0.11).
The associations of prolactin and BDNF levels with the
presence of depression was non-significant: OR 1.19 (95%CI
0.85; 1.68) for ln(prolactin), and OR 1.03 (95%CI 0.58; 1.84) for
ln(BDNF). The genetic associations with depression status were
similarly non-significant: rs1341239 OR 0.90 (95%CI 0.60; 1.36),
rs6265 OR 0.62 (95%CI 0.35; 1.11), and OR 1.24 rs7124442 (95%
CI 0.78; 1.97).
As mentioned before we did not observe any deviation for an
additive genetic model. Furthermore, and despite the gender by
age interaction on prolactin, we did not observe a similar gender
or age modification of the genetic association with either
depression status or prolactin/BDNF.DISCUSSION
In our study, we found an association of rs6265 with the severity
of depression according to the patient's HAMD-17 as well as
CGI-S scores at admission to the hospital. The other studied
genetic variants showed no significant relationship with theTABLE 1 | Characteristics of genotyped individuals.
Healthy controls
Characteristics n = 94
Gender Male: 27 (28%); Female: 67 (72%)
Mean age in years (sd) 33.82 (11.50)
Median prolactin in ln(pg/ml) (Q1; Q3) 4.35 (2.51; 5.63) 6.14 (3.53; 9.23)
Median BDNF in ln(pg/ml) (Q1; Q3) 4.23 (2.94; 6.51)
Patients with depression
Characteristics n = 186
Gender Male: 17 (9%); Female: 169 (91%)
Mean age in years (sd) 49.93 (10.75)
Median HAMD-17 (Q1; Q3) 24 (21; 28)
Median prolactin in ln(pg/ml) (Q1; Q3) 5.58 (3.53; 8.12) 5.46 (3.15; 10.37)
Median BDNF in ln(pg/ml) (Q1; Q3) 4.31 (3.10; 6.10)Nb sd, standard deviation; Q1 and Q3, quartile's 1 and 3; ln, natural logarithm.FIGURE 1 | A dot and line plot of age and prolactin stratified by gender and depression status. N.b. Depicted lines are derived from subgroup specific linear
regression models.February 2020 | Volume 11 | Article 38
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associations were determined by sequentially regressing
outcome variables on the available SNPs, which decreases the
vulnerability for incorrect classification of disease in individuals;Frontiers in Psychiatry | www.frontiersin.org 5patients may suffer from different neurobiological disorders
causing their major depression, and healthy probands may
develop a major depression during their later life. We removed
persons with missing genotype identity; this decreases theFIGURE 2 | A dot plot of the HAMD-17 by number of minor allele in depressed patients, observations were color-coded based on a 24 cut-off. N.b. the diamond
shape indicates the median HAMD-17; MD, mean difference from an additive genetic model; 95%CI, 95% confidence interval.February 2020 | Volume 11 | Article 38
Losenkov et al. BDNF and PRL Polymorphism and Depressionstatistical power, but more importantly eliminates the distortion
by studying different groups of persons for every SNP. We have
no reason to believe that genotype data are missing in a non-
randommanner. We have also genotyped BDNF rs11030104, but
unfortunately the results violated the Hardy-Weinberg
equilibrium distribution and had to be excluded from further
analyses. However, BDNF rs11030104 is partially in equilibrium
with BDNF rs6265 (Supplementary Image 1), which limits the
loss of these results. Neither the PRL SNP nor the BDNF SNPs
were associated with the absolute levels of these neurotrophic
factors. These actual PRL and BDNF levels were additionally not
significantly associated with the presence of depression. This lack
of association indicates that rs6265 is related to a pathogenetic
element contributing to the vulnerability of becoming severely
depressed and less to mediating the actual severity of this
depression (by modulating actual BDNF expression). We
expected that the likelihood of a possible association with a
relevant genotype would be higher in severely depressed patients,
but we could not demonstrate this due to the low number of
patients with two minor alleles.
The composition of the studied patient population differs
from the healthy control group. Certain selection bias is
inevitable. Some healthy individuals will be prone to develop a
depression and will probably get a depression during their later
life. Individuals of female gender have a larger chance of
becoming depressed, and also an older age could be an
expected finding in at least moderate depressed patients (30).
This is particularly relevant for the analysis using PRL levels.
Premenopausal women have significantly higher PRL levels than
postmenopausal female persons, who have not significantly
different levels in comparison to men (31–33). This might be
related to modulation of PRL dynamics by estrogen levels (31).
Compared to the patient group only a very limited number of
female controls of our study were of higher age. This might have
decreased the difference in the mean PRL levels of depressed vs
healthy persons. However, a similar relationship between PRL
levels and age was obvious, and PRL levels were generally higher
in depressed women in spite of the expected premenopausal
versus postmenopausal study group composition (Figure 1).
Nevertheless, it could be useful in the future to measure PRL
well before midcycle in still menstruating women, check for
(natural or exogenous) estrogen status in female persons, and
match control subjects for age with women.
BDNF has been widely investigated with respect to major
depressive disorder as well as bipolar disorder (4, 34). In major
depression, there exists a clear relationship between BDNF levels
and the depressive state, as well as the success of antidepressant
therapy (4). The results of one of the last meta-analysis present
evidence that supported the hypothesis that BDNF Val66Met
polymorphism moderated the relationship between stress and
depression, despite the fact that many included individual studies
did not show this effect (35). We did not reproduce this finding
concerning BDNF levels but observed an association between
BDNF rs6265 and the severity of depression. The association
observed in the present study could correspond to such a
neuroplastic mechanism, which would make the individualFrontiers in Psychiatry | www.frontiersin.org 6becoming more easily and more severely depressed than
other persons.Strength and Limitations
We studied 185 newly admitted patients who had not been
treated with antidepressant drugs during their current depressive
episode (operationalized to at least 6 months in patients with
recurrent depression). Of these patients, 54.5% had never been
treated with antidepressant drugs during their entire life. About
half of these patients were seriously depressed according to the
criteria of Zimmerman et al. (36). We only considered persons
who were genotyped for all three considered variants, which
largely improves the reliability of the observed associations.
However, although reasonably sized for a biomarker study, our
sample size after selecting these persons is relatively small for a
pharmacogenetics study. Moreover, a certain gender imbalance
between patients and controls is evident and postmenopausal
patients were relatively scarce within the control group.
Nevertheless, we observed a significant association between
BDNF rs6265 and the severity of depression, which might
mean that this reflects a relatively robust effect.
Conclusions
We observed a significant association between BDNF gene
variant rs6265 and the severity of depression in newly
admitted, antidepressant treatment-free, depressed patients.
Actual PRL and BDNF levels were not elevated sufficiently in
depressed patients to reach statistical significance and were not
associated with the studied genotypes.DATA AVAILABILITY STATEMENT
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